Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Anteris Technologies Global Corp. (AVR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$5.58-8.82%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AVR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain financial stability after debt issuance | A supporting condition in Anteris Technologies Global Corp.'s published investment case. The stated target is No liquidity crisis or debt default post-May 2026 issuance. | Intact | Debt covenant breach or liquidity shortfall after debt issuance | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
AVR is a speculative, development-stage healthcare story rather than an established earnings compounder. The long-term thesis is on watch: management is advancing the PARADIGM Trial, but the company is loss-making and recent financial performance has been weak.
AVR is valued at a substantial premium to peers, with optionality driving the valuation and low confidence in the valuation model. The evidence says that expensive valuation is priced in, but not the full combination of weak performance and turbulent conditions.
Near term, earnings risk is elevated after repeated misses, including the August 2026 miss, and recent performance has lagged its industry cohort. Management says advancing the PARADIGM Trial is a priority, and reported revenue rose from $494,000 in Q1 to $1,009,000 in Q2 while operating cash outflows fell from $28.7 million to $20.8 million. These changes align with trial-related activity, but do not yet establish a stronger earnings base.
Over the multi-year view, the central swing factor is progress in the PARADIGM Trial and whether management continues to meet its stated execution milestones. Near term, a weakening jobs trend could add pressure to cyclical healthcare names, while continued strong results from sector bellwethers ABT, MDT, and SYK could sustain sector momentum; weaker results or guidance from those companies could remove that support.
AVR’s long-term thesis has a clinical-development basis, but current evidence shows losses, weak performance, elevated near-term risk, and a premium valuation. The 1-3 year view depends on trial execution and whether the business shows more durable financial progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It leased new office and warehouse space. |
| Intact |
| Failure to utilize leased space or lease termination |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Successful termination of development contributions with v2vmedtech | Anteris is working to stop costly development with v2vmedtech. | Intact | Resumption of development contributions with v2vmedtech or increased related costs | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows to at least $19.9 million in FY27 | A primary condition in Anteris Technologies Global Corp.'s published investment case. The stated target is >= $19,930,250. | Broken | Revenue falls below $13.9 million in FY26 or fails to grow toward $19.9 million in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.98 → $-1.22 · observed estimates
$0.02B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.98 | $16,575,000 | 1 / 3 |
| 2026-07-25 | $-0.98 | $16,575,000 | 1 / 3 |
| 2026-07-26 | $-0.98 | $16,575,000 | 1 / 3 |
| 2026-07-27 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-07-28 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-07-29 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-07-30 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-07-31 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-01 | $-0.98 | $16,575,000 | 2 / 3 |
| 2026-08-02 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-03 | $-0.98 | $16,575,000 | 2 / 3 |
| 2026-08-04 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-05 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-06 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-07 | $-0.98 | $16,575,000 | 2 / 3 |
| 2026-08-08 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-09 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-10 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-11 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-12 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-13 | $-0.98 | $19,930,250 | 3 / 4 |
| 2026-08-14 | $-0.98 | $16,575,000 | 2 / 3 |
| 2026-08-15 | $-0.98 | $16,575,000 | 1 / 3 |
| 2026-08-16 | $-0.98 | $16,575,000 | 1 / 3 |
| 2026-08-17 | $-0.98 | $16,575,000 | 1 / 3 |
| 2026-08-18 | $-0.98 | $16,575,000 | 1 / 3 |
| 2026-08-19 | $-0.98 | $16,575,000 | 1 / 3 |
| 2026-08-20 | $-0.98 | $16,575,000 | 1 / 3 |
| 2026-08-21 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-22 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-23 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-24 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-25 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-26 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-27 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-28 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-29 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-30 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-08-31 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-01 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-02 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-03 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-04 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-05 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-06 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-07 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-08 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-09 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-10 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-11 | $-1.13 | $10,000,000 | 1 / 3 |
| 2026-09-12 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-13 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-14 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-15 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-16 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-17 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-18 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-19 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-20 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-21 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-22 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-23 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-24 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-25 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-26 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-27 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-28 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-29 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-09-30 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-10-01 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-10-02 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-10-03 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-10-04 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-10-05 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-10-06 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-10-07 | $-1.13 | $10,000,000 | 2 / 3 |
| 2026-10-08 | $-1.17 | $10,000,000 | 2 / 3 |
| 2026-10-09 | $-1.17 | $10,000,000 | 2 / 3 |
| 2026-10-10 | $-1.17 | $10,000,000 | 2 / 3 |
| 2026-10-11 | $-1.17 | $10,000,000 | 2 / 3 |
| 2026-10-12 | $-1.17 | $10,000,000 | 2 / 3 |
| 2026-10-13 | $-1.17 | $10,000,000 | 2 / 3 |
| 2026-10-14 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-15 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-16 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-17 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-18 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-19 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-20 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-21 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-22 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-23 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-24 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-25 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-26 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-27 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-28 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-29 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-30 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-10-31 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-11-01 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-11-02 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-11-03 | $-1.22 | $10,000,000 | 2 / 3 |
| 2026-11-04 | $-1.22 | $10,000,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.